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Background
Numerous studies have compared the outcomes of two competing interventions for 
multivessel coronary artery disease: coronary-artery bypass grafting (CABG) and 
coronary stenting. However, little information has become available since the intro-
duction of drug-eluting stents.
Methods
We identified patients with multivessel disease who received drug-eluting stents or 
underwent CABG in New York State between October 1, 2003, and December 31, 
2004, and we compared adverse outcomes (death, death or myocardial infarction, 
or repeat revascularization) through December 31, 2005, after adjustment for dif-
ferences in baseline risk factors among the patients.
Results
In comparison with treatment with a drug-eluting stent, CABG was associated with 
lower 18-month rates of death and of death or myocardial infarction both for patients 
with three-vessel disease and for patients with two-vessel disease. Among patients 
with three-vessel disease who underwent CABG, as compared with those who re-
ceived a stent, the adjusted hazard ratio for death was 0.80 (95% confidence interval 
[CI], 0.65 to 0.97) and the adjusted survival rate was 94.0% versus 92.7% (P = 0.03); 
the adjusted hazard ratio for death or myocardial infarction was 0.75 (95% CI, 0.63 
to 0.89) and the adjusted rate of survival free from myocardial infarction was 92.1% 
versus 89.7% (P<0.001). Among patients with two-vessel disease who underwent 
CABG, as compared with those who received a stent, the adjusted hazard ratio for 
death was 0.71 (95% CI, 0.57 to 0.89) and the adjusted survival rate was 96.0% 
versus 94.6% (P = 0.003); the adjusted hazard ratio for death or myocardial infarction 
was 0.71 (95% CI, 0.59 to 0.87) and the adjusted rate of survival free from myocar-
dial infarction was 94.5% versus 92.5% (P<0.001). Patients undergoing CABG also 
had lower rates of repeat revascularization.
Conclusions
For patients with multivessel disease, CABG continues to be associated with lower 
mortality rates than does treatment with drug-eluting stents and is also associated 
with lower rates of death or myocardial infarction and repeat revascularization.
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Several studies have compared the long-term out-
comes of coronary-artery bypass grafting (CABG) 
and coronary stenting.1-5 In 2003, drug-eluting 
stents were introduced for the purpose of reduc-
ing restenosis, which has continued to be a prob-
lem associated with the use of bare-metal stents. 
Many randomized, controlled trials have docu-
mented lower rates of clinical and angiographic 
restenosis,  target-lesion  revascularization,  and 
major adverse cardiac events with drug-eluting 
stents.6-20 However, recent reports of the danger 
of  late  stent  thrombosis  among  patients  with 
drug-eluting stents21,22 led to a meeting of a Food 
and Drug Administration (FDA) advisory com-
mittee that addressed the safety of drug-eluting 
stents.23,24
Consequently, it is not clear whether the rela-
tive  outcomes  reported  in  earlier  studies  that 
compared CABG with coronary stenting are re-
flective of current practice. The purpose of this 
study  is  to  compare  rates  of  death,  death  or 
myocardial infarction, and subsequent revascu-
larization  in  patients  receiving  drug-eluting 
stents and those undergoing CABG in New York 
State.
Methods
Databases
The two primary databases used in the study 
were  the  Cardiac  Surgery  Reporting  System 
(CSRS) and the Percutaneous Coronary Interven-
tion Reporting System (PCIRS) of the New York 
State  Department  of  Health.  These  registries 
were developed in 1989 and 1991, respectively, 
for the purpose of collecting information on all 
residents of New York State who undergo CABG 
and percutaneous coronary intervention (PCI) in 
nonfederal hospitals in the state. The registries 
contain information on demographics, coexist-
ing conditions, left ventricular function, hemo-
dynamic state, diseased vessels and vessels for 
which  surgery  or  angioplasty  was  attempted, 
hospital and operator identifiers, and in-hospital 
adverse outcomes. Uniform definitions for these 
elements are used in the databases. The PCIRS 
also contains information on the type or types of 
device used for each patient, including bare-met-
al stents and drug-eluting stents. Efforts to en-
sure the accuracy and completeness of these data 
have been described elsewhere.5
Information on deaths of residents of New 
York State after discharge from the hospital was 
obtained by matching the patients in each of the 
registries  with  the  state  Vital  Statistics  Death 
file with the use of patient identifiers. CSRS and 
PCIRS were also linked with the state adminis-
trative  acute  care  discharge-reporting  system, 
the Statewide Planning and Research Coopera-
tive System (SPARCS). The SPARCS contains in-
formation  on  patient  demographics  (age,  sex, 
and race), diagnoses and procedures, admission 
and discharge dates, and discharge disposition 
for  all  patients  discharged  from  nonfederal 
acute care hospitals in New York State. CSRS 
and PCIRS records were matched with SPARCS 
records  by  using  unique  hospital  identifiers 
along with patient identifiers and dates of ad-
mission,  surgery,  and  discharge.  Subsequent 
emergency hospitalizations with myocardial in-
farction  as  the  principal  diagnosis  were  then 
identified.
Study Group and End points
The  study  includes  patients  who  were  treated 
with drug-eluting stents (with or without other 
devices) or CABG from October 1, 2003, to De-
cember 31, 2004. This strategy was chosen to 
avoid the start-up period for drug-eluting stents 
between April and September 2003.
Patients were excluded if they had previously 
undergone revascularization (6061 patients), had 
left main coronary artery disease (3188 patients), 
had had a recent  myocardial infarction (within 
24 hours before treatment) (1768 patients), or 
were not residents of New York State (678 pa-
tients).  The  remaining  patients,  who  included 
9963 patients receiving drug-eluting stents and 
7437 patients undergoing CABG between Octo-
ber 1, 2003, and December 31, 2004, were fol-
lowed through December 31, 2005, for myocar-
dial infarction resulting in readmission, death, 
and repeat revascularization.
The end points of the study were death in the 
hospital or within 30 days after treatment and 
death, death or myocardial infarction, and re-
vascularization up to 18 months after treatment. 
Myocardial  infarctions  as  complications  were 
defined as either complications at the index ad-
mission (defined as new Q waves in both the 
CSRS and the PCIRS) or myocardial infarctions 
at readmission (defined as an emergency admis-
sion with a principal diagnosis of myocardial 
infarction).
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Statistical Analysis
The main purpose of the study was to compare 
differences in adverse outcomes between the two 
procedures. Another purpose, identified at the 
beginning of the study, was to compare adverse 
outcomes in subgroups of patients at high risk 
(patients with diabetes, patients 80 or more years 
of age, and patients with low left ventricular ejec-
tion fractions).
The prevalence rates of risk factors and char-
acteristics (demographic features, left ventricu-
lar  function,  hemodynamics,  and  coexisting 
conditions) of the patients in the two treatment 
groups  were  compared  by  the  chi-square  test 
and Fisher’s exact test. Kaplan–Meier estimates 
were used to plot the rates of subsequent revas-
cularization; data from patients who died before 
subsequent revascularization were censored. The 
risk-adjusted odds ratios for in-hospital and 30-
day mortality were calculated with the use of a 
stepwise logistic-regression model with patient 
risk factors as independent control variables and 
type of procedure included in the model as the 
independent study variable of interest.
Differences in risk-adjusted, long-term rates 
of death and of death or myocardial infarction 
between patients undergoing the two procedures 
were  investigated  by  developing  stepwise  Cox 
proportional-hazards models after confirmation 
that the proportional-hazards assumption was 
justified.25 Candidate independent variables in-
cluded left ventricular function, hemodynamics, 
and coexisting conditions. Treatment type (drug-
eluting  stent  or  CABG)  was  included  in  each 
model in order to obtain hazard ratios for CABG 
as compared with drug-eluting stent after ad-
justment for covariates that are significant pre-
dictors  of  adverse  outcomes.  Separate  models 
were  developed  for  combinations  of  the  two 
outcomes and four anatomical groups defined 
by the number of diseased vessels and by the 
presence or absence of disease in the proximal 
left anterior descending (LAD) coronary artery. 
Data from patients with two-vessel disease who 
had no LAD artery disease and from patients 
with two-vessel disease who had nonproximal 
LAD artery disease were combined because of 
sample-size  considerations  and  similar  out-
comes. Separate models were developed for each 
of the outcomes for all patients with three-vessel 
disease and all patients with two-vessel disease. 
Disease was defined as stenosis of at least 70%. 
Two-vessel disease was defined as disease in two 
of the three major epicardial vessels, and three-
vessel disease as disease in all three vessels.
Adjusted Kaplan–Meier survival curves were 
constructed for each type of procedure for pa-
tients with two-vessel and three-vessel disease 
with  the  use  of  the  Cox  proportional-hazards 
models  and  methods  for  calculating  adjusted 
survival.26  Cox  proportional-hazards  models 
were also used to test for significance of the 
hazard ratios for three subgroups of patients: 
patients with diabetes, patients 80 or more years 
of age, and patients with left ventricular ejection 
fractions below 40%.
A propensity model was then used to test for 
selection bias.27,28 The significant predictors of 
type of procedure (CABG or drug-eluting stent) 
were identified by fitting a stepwise logistic-re-
gression model with a binary dependent variable 
representing  CABG  versus  drug-eluting  stent, 
with candidate variables consisting of the pa-
tient-related predictors of the type of procedure 
used. For each anatomical group, the patients’ 
propensity scores were subdivided into quartiles, 
and risk-adjusted hazard ratios for CABG versus 
drug-eluting stent were computed for each quar-
tile. Hazard ratios were compared across quar-
tiles. All reported P values are two-sided and are 
not adjusted for multiple testing. All analyses 
were performed with SAS software (version 9.1).
Results
Table 1 presents the prevalence rates of risk fac-
tors  among  patients  treated  with  CABG  and 
among those treated with drug-eluting stents. 
Patients undergoing CABG were on average older 
(although more patients over 80 years of age were 
treated with stents than with CABG) and were 
more likely to be male, to be non-Hispanic, to be 
white, to have lower ejection fractions, to have 
had previous myocardial infarctions, to have oth-
er coexisting conditions, and to have three-vessel 
disease. There were no significant differences 
between the two groups in the risk-adjusted rates 
of in-hospital or 30-day mortality (adjusted odds 
ratio, 1.29; 95% confidence interval [CI], 0.92 to 
1.81; P = 0.15).
Figure 1 shows that the rate of revasculariza-
tion within 18 months after the initial procedure 
was higher for patients receiving drug-eluting 
stents.  Of  patients  who  received  drug-eluting 
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stents, 28.4% underwent repeat PCI (e.g., stent-
ing or balloon angioplasty) and 2.2% underwent 
CABG within 18 months. The respective rates 
for patients undergoing CABG were 5.1% and 
0.1%; both differences are statistically signifi-
cant (P<0.001). Of patients who received drug-
eluting  stents,  12.5%  underwent  repeat  PCI 
within 30 days and 18.3% underwent repeat PCI 
within 60 days. Many of these patients may have 
undergone planned PCI associated with incom-
plete revascularization during the index admis-
sion. Of the 28.4% of patients who underwent 
repeat PCI during the study period, only a little 
more than one quarter (7.0%) underwent target-
vessel revascularization.
The mean follow-up times were 19.1 months 
for patients undergoing CABG and 18.7 months 
for those receiving drug-eluting stents. Table 2 
presents follow-up times according to treatment 
and  anatomical  group.  Table  2  also  presents 
adjusted hazard ratios (CABG vs. drug-eluting 
stent) for mortality among patients in six ana-
tomical  groups:  all  patients  with  three-vessel 
disease, those with three-vessel disease includ-
ing  proximal  LAD  artery  involvement,  those 
with three-vessel disease without proximal LAD 
artery involvement, all patients with two-vessel 
disease, those with two-vessel disease including 
proximal  LAD  artery  involvement,  and  those 
with two-vessel disease without proximal LAD 
artery involvement. Figures 2 and 3 present the 
18-month unadjusted and adjusted rates of sur-
Table 1. Risk Factors in Patients Treated with CABG or Drug-Eluting Stents.*
Risk Factor
CABG
(N = 7437)
Stent
(N = 9963) P Value
Age (%) <0.001
<50 yr 7.6 9.7
50–59 yr 20.7 23.1
60–69 yr 30.2 27.6
70–79 yr 31.3 26.9
≥80 yr 10.2 12.7
Median age (yr) 67.0 66.0 <0.001
Mean age (yr) 66.0±10.9 65.4±11.9 <0.001
Sex (%) <0.001
Male 72.5 67.2
Female 27.5 32.8
Hispanic ethnic background (%)† 6.9 9.3 <0.001
Race (%)† <0.001
White 87.7 82.1
Black 7.1 10.1
Other 5.2 7.9
Ejection fraction (%) <0.001
<20% 2.0 0.8
20–29% 6.8 3.3
30–39% 12.9 6.6
≥40% 77.7 84.2
Data missing 0.6 5.1
Previous myocardial infarction (%) <0.001
1–7 days before treatment 20.5 18.9
8–20 days before treatment 5.6 2.5
≥21 days before treatment 21.4 12.3
No previous myocardial infarction  52.5 66.3
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vival and survival free from myocardial infarc-
tion for patients with three-vessel disease treated 
with drug-eluting stents or CABG and for those 
with two-vessel disease treated with drug-elut-
ing stents or CABG.
As indicated in Table 2 and Figure 3, CABG 
was  associated  with  lower  18-month  rates  of 
death  and  of  death  or  myocardial  infarction 
than  treatment  with  a  drug-eluting  stent  for 
patients  with  three-vessel  disease  and  for  pa-
tients with two-vessel disease. Among patients 
with three-vessel disease who were treated with 
CABG,  as  compared  with  those  who  received 
stents, the adjusted hazard ratio for death was 
0.80 (95% CI, 0.65 to 0.97), and the adjusted 
survival rate was 94.0% versus 92.7% (P = 0.03); 
the adjusted hazard ratio for death or myocar-
dial infarction among this group of patients was 
0.75 (95% CI, 0.63 to 0.89), and the adjusted 
rates of survival free from myocardial infarction 
were 92.1% versus 89.7% (P<0.001). 
Among patients with two-vessel disease treat-
ed  with  CABG,  the  adjusted  hazard  ratio  for 
death was 0.71 (95% CI, 0.57 to 0.89) and the 
adjusted survival rates were 96.0% versus 94.6% 
(P = 0.003); the adjusted hazard ratio for death or 
myocardial infarction among this group of pa-
tients was 0.71 (95% CI, 0.59 to 0.87), and the 
adjusted rates of survival free from myocardial 
infarction were 94.5% versus 92.5% (P<0.001). 
CABG  was  also  associated  with  significantly 
lower mortality in patients with two-vessel dis-
ease  either  with  involvement  of  the  proximal 
LAD artery (adjusted hazard ratio, 0.71; 95% CI, 
0.53  to  0.96)  or  without  involvement  of  the 
proximal  LAD  artery  (adjusted  hazard  ratio, 
0.69; 95% CI, 0.48 to 0.98).
Table 3 presents the rates of death and of 
Table 1. (Continued.)
Risk Factor
CABG
(N = 7437)
Stent
(N = 9963) P Value
Cerebrovascular disease (%) 17.3 7.7 <0.001
Peripheral arterial disease (%) 10.7 7.0 <0.001
Hemodynamic instability or shock (%) 1.8 0.2 <0.001
Congestive heart failure (%) <0.001
None 84.3 89.9
At current admission 12.6 7.4
Before current admission 3.1 2.7
Malignant ventricular arrhythmia (%) 0.7 0.4 0.03
Chronic obstructive pulmonary disease (%) 17.4 6.6 <0.001
Diabetes (%) 38.2 32.7 <0.001
Renal failure (%) 0.01
Requiring dialysis 2.2 2.4
Creatinine >2.5 mg/dl (220 μmol/liter) 2.0 1.4
No renal failure 95.8 96.3
No. of diseased vessels (%)‡ <0.001
3, with proximal LAD artery  51.5 11.8
3, without proximal LAD artery 18.4 13.1
2, with proximal LAD artery 20.0 26.1
2, without proximal LAD artery 10.1 49.0
* Plus–minus values are means ±SD. Because of rounding, percentages may not total 100. CABG denotes coronary­artery 
bypass grafting, and LAD left anterior descending.
† Race or ethnic group was reported by the Cardiac Surgery Reporting System and the Percutaneous Coronary Intervention 
Reporting System registries.
‡ Diseased vessels were defined by the presence of stenosis of at least 70%.
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Figure 1. Rates of Revascularization within 18 Months after Initial Procedure.
CABG denotes coronary­artery bypass grafting, and PCI percutaneous coronary intervention.
Table 2. Hazard Ratios for Death and for Death or Myocardial Infarction after CABG and after Treatment with a Drug-Eluting Stent, 
According to Number of Diseased Vessels.*
Variable
No. of  
Patients
Mean 
Follow-up Death Death or Myocardial Infarction
No. of  
Events
Adjusted Hazard 
Ratio (95% CI)† P Value
No. of 
Events
Adjusted Hazard 
Ratio (95% CI)† P Value
mo
3 Diseased vessels 
With or without proximal LAD artery
CABG  5202 19.1 346 0.80 (0.65–0.97) 0.03 449 0.75 (0.63–0.89) <0.001
Stent 2481 18.5 171 Reference 249 Reference
With proximal LAD artery
CABG  3833 19.1 257 0.79 (0.61–1.02) 0.07 331 0.77 (0.61–0.96) 0.02
Stent 1178 18.5   85 Reference 117 Reference
Without proximal LAD artery 
CABG 1369 19.1   89 0.79 (0.58–1.09) 0.15 118 0.69 (0.53–0.91) 0.008
Stent 1303 18.5   86 Reference 132 Reference
2 Diseased vessels
With or without proximal LAD artery
CABG 2235 19.2 118 0.71 (0.57–0.89) 0.003 156 0.71 (0.59–0.87) <0.001
Stent 7482 18.7 397 Reference 555 Reference
With proximal LAD artery
CABG 1486 19.2   80 0.71 (0.53–0.96) 0.02 105 0.72 (0.56–0.93) 0.01
Stent 2600 18.6 143 Reference 201 Reference
Without proximal LAD artery 
CABG   749 19.1   38 0.69 (0.48–0.98) 0.04 51 0.71 (0.52–0.96) 0.03
Stent 4882 18.8 254 Reference 354 Reference
* CABG denotes coronary­artery bypass grafting, and LAD left anterior descending.
† Hazard ratios are adjusted for age; sex; ejection fraction; hemodynamic state; history or no history of myocardial infarction before proce­
dure; presence or absence of cerebrovascular disease, peripheral arterial disease, congestive heart failure, chronic obstructive pulmonary 
disease, diabetes, and renal failure; and involvement of the proximal LAD artery.
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death  or  myocardial  infarction  for  three  sub-
groups  of  patients  treated  with  drug-eluting 
stents or CABG who were chosen at the outset 
of the study. There were no significant differ-
ences in mortality among any of the subgroups. 
However, the rate of death or myocardial infarc-
tion  was  significantly  lower  for  those  treated 
with CABG among patients with ejection frac-
tions  below  40%  (adjusted  hazard  ratio,  0.67; 
95% CI, 0.53 to 0.84) and patients who were at 
least 80 years old (adjusted hazard ratio, 0.74; 
95% CI, 0.56 to 0.96).
Significant covariates in the propensity analy-
sis included age; sex; race; ethnic group; ejection 
fraction; history or no history of myocardial in-
farction; presence or absence of peripheral vas-
cular disease, hemodynamic instability, conges-
tive heart failure, chronic obstructive pulmonary 
disease,  and  diabetes;  and  anatomical  group 
(number of diseased vessels and the presence or 
absence  of  proximal  LAD  artery  disease).  For 
each  of  the  12  combinations  of  anatomical 
group and outcome (six anatomical groups and 
two outcome measures), the advantage of CABG 
was  quite  consistent,  with  only  11  of  the  48 
quartiles having adjusted hazard ratios that were 
larger than 1 and nonsignificant.
Discussion
The two primary interventions for patients with 
multivessel  coronary  artery  disease  are  CABG 
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Figure 2. Unadjusted Curves for Long-Term Survival and Survival Free from Myocardial Infarction According to the Number of Diseased 
Vessels.
Panels A through D show unadjusted survival curves and the numbers of patients at risk. CABG denotes coronary­artery bypass grafting.
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and PCI. Several randomized, controlled trials 
and  observational  studies  have  compared  the 
long-term outcomes of these two interventions, 
but these studies all preceded the introduction of 
drug-eluting  stents.1-5  Consequently,  the  find-
ings of these studies are outdated and may no 
longer reflect current relative outcomes. For in-
stance,  many  studies  have  compared  the  out-
comes of drug-eluting and bare-metal stents, and 
the majority of these studies have concluded that 
drug-eluting stents compare favorably with bare-
metal stents with regard to target-lesion steno-
sis, target-vessel stenosis, or both, or repeat-
  revascularization rates.6-20 Conversely, two reports 
have warned about the danger of late stent throm-
bosis among patients with drug-eluting stents,21,22 
leading to an FDA meeting that addressed the 
safety of drug-eluting stents.23,24 Thus, it is un-
clear how the long-term outcome of drug-eluting 
stents compares with that of CABG.
The purpose of this observational study was 
to compare rates of death and repeat revascular-
ization among patients treated with CABG and 
among those treated with drug-eluting stents in 
New York State between October 1, 2003, and 
December 31, 2004, and in follow-up observa-
tions, to compare rates of death, death or myo-
cardial infarction, and repeat revascularization 
in these two groups of patients through Decem-
ber 31, 2005. The major findings of the study 
were that among patients with three-vessel dis-
ease or two-vessel disease, those treated with 
CABG had significantly lower adjusted rates of 
death  and  of  death  or  myocardial  infarction 
than those treated with drug-eluting stents; that 
CABG was associated with lower rates of death 
or  myocardial  infarction  for  all  subgroups  of 
patients with multivessel disease defined by the 
presence or absence of proximal LAD artery dis-
ease; that for the mortality outcome, there were 
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Figure 3. Adjusted Curves for Long-Term Survival and Survival Free from Myocardial Infarction According to the Number of Diseased 
Vessels.
Panels A through D show survival curves adjusted for age; sex; ejection fraction; hemodynamic state; history or no history of myocardial 
infarction before the procedure; the presence or absence of cerebrovascular disease, peripheral arterial disease, congestive heart failure, 
chronic obstructive pulmonary disease, diabetes, and renal failure; and involvement of the proximal left anterior descending (LAD) artery. 
CABG denotes coronary­artery bypass grafting.
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no significant differences between drug-eluting 
stents and CABG for patients with three-vessel 
disease, with or without proximal LAD artery 
disease, but there was a trend in favor of CABG; 
and that in three high-risk subgroups of patients 
(patients with diabetes, patients with left ven-
tricular ejection fractions below 40%, and pa-
tients 80 years of age or older), there were no 
significant  differences  in  adjusted  mortality 
rates  between  those  undergoing  CABG  and 
those receiving drug-eluting stents, but patients 
with ejection fractions below 40% and patients 
who were at least 80 years old who underwent 
CABG had significantly lower rates of death or 
myocardial infarction. A caveat of the findings 
for the three high-risk subgroups is that there 
may be unmeasured confounding in the data. 
For example, data on the severity of diabetes and 
insulin dependence were not available, and to the 
extent that one treatment (e.g., CABG) is associ-
ated with more severe diabetes, the risk-adjust-
ment process was unable to control for those 
differences.
Our  earlier  study  conducted  in  New  York 
State compared the outcomes of CABG and bare-
metal stents.5 That study, which examined the 
rate of death but not the rate of death or myo-
cardial infarction, found that the adjusted mor-
tality rates were lower for CABG than for bare-
metal stents in all subgroups of patients defined 
on the basis of the number of diseased vessels 
and the presence or absence of proximal LAD 
artery disease. The hazard ratios ranged from 
0.64  for  patients  with  three-vessel  disease  in-
cluding the proximal LAD artery to 0.76 for pa-
tients with two-vessel disease without involve-
ment of the proximal LAD artery.5 
The primary difference between the findings 
of this earlier study and the present study is that 
the earlier study found significantly lower death 
rates after CABG than after stenting in all sub-
groups of patients defined on the basis of loca-
tion of disease, whereas we report here that two 
of  these  subgroups  did  not  have  lower  death 
rates after CABG than after stenting. However, 
the current study did find lower rates of death or 
myocardial  infarction  after  CABG  than  after 
stenting in all subgroups of patients.
An important caveat of the present study and 
the earlier one is that both were observational 
studies and are therefore subject to potential bias 
with respect to the relative preprocedural sever-
ity of illness among patients treated with CABG 
and drug-eluting stents. There are a few ways 
to test for and to minimize this bias, including 
propensity analyses and instrumental variables 
Table 3. Hazard Ratios for Death and for Death or Myocardial Infarction after CABG and after Treatment with a Drug-Eluting Stent, 
According to Selected Subgroups of Patients.*
Variable
No. of 
Patients
Mean 
Follow-up Death Death or Myocardial Infarction
No. of 
Events
Adjusted Hazard 
Ratio (95% CI)† P Value
No. of 
Events
Adjusted Hazard 
Ratio (95% CI)† P Value
mo
Diabetes
CABG 2844 18.9 242 0.97 (0.77–1.20) 0.75 304 0.84 (0.69–1.01) 0.07
Stent 3256 18.5 224 Reference 343 Reference
Ejection fraction <40%
CABG 1614 18.6 181 0.77 (0.59–1.00) 0.05 213 0.67 (0.53–0.84) <0.001
Stent 1059 17.8 144 Reference 183 Reference
Age ≥80 yr
CABG 760 18.0 107 0.74 (0.55–1.00) 0.05 125 0.74 (0.56–0.96) 0.03
Stent 1266 17.8 175 Reference 216 Reference
* CABG denotes coronary­artery bypass grafting, and LAD left anterior descending. 
† Hazard ratios are adjusted for age; sex; ejection fraction; hemodynamic state; history or no history of myocardial infarction before proce­
dure; presence or absence of cerebrovascular disease, peripheral arterial disease, congestive heart failure, chronic obstructive pulmonary 
disease, diabetes, and renal failure; number of diseased vessels; and involvement of the proximal LAD artery. 
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in conjunction with adjustments to account for 
differences in measures of underlying preproce-
dural risk.29 As in our earlier comparison of bare-
metal stents versus CABG, we chose to use pro-
pensity analyses, whereby the existence of constant 
treatment effects can be tested for by subdivid-
ing patients into propensity groups on the basis 
of a score obtained from a logistic-regression 
model, with predictors of treatment type as in-
dependent variables and treatment type as a bi-
nary dependent variable.
Our propensity analyses demonstrate that the 
relative outcomes associated with the two proce-
dures remained about the same, regardless of the 
propensity to choose one procedure over the oth-
er, indicating that the results are not likely to be 
severely compromised by selection bias. Further-
more, observational studies such as ours are of 
value because they shed light on the use of com-
peting treatment options in current practice and 
because they include patients at high risk who 
are frequently not represented in clinical trials. 
Nevertheless, despite our efforts to eliminate bias 
as much as possible, in an observational study 
there is no way to eliminate bias caused by the 
presence of patients who would not have been in 
a randomized, controlled trial because they would 
have had contraindications or would have been 
deemed to be ineligible for one of the procedures, 
or by the presence of pairs of patients who dif-
fer with respect to unmeasured risk factors not 
contained in the registries.
Another caveat is that, as in our previous 
study, we did not have access to data on deaths 
occurring outside of New York. We limited the 
study to residents of New York State and elimi-
nated out-of-state patients who underwent the 
procedures in New York hospitals. However, if a 
New  York  resident  moved  from  the  state  and 
died elsewhere, information on the death was 
not available to us. Consequently, it must be as-
sumed that the likelihood of a patient’s dying 
outside of New York was not associated with the 
type of procedure undergone by the patient.
Finally, we would like to have used a longer 
follow-up period, but more recent mortality data 
are not available at this time. Nevertheless, it 
would appear that the advantage of CABG would 
have persisted over the course of another year or 
two of follow-up, both because our earlier, longer 
study5 showed evidence of that tendency and be-
cause there is evidence of very late stent throm-
bosis in patients receiving drug-eluting stents.21
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